ERBB2 and neoplasm: In our study, elevated levels of HER2/ECD correlated positively with parameters related to tumor aggressiveness, such as vascular invasion, metastatic status, or negativity of estrogen receptors, but not with invaded lymph nodes and progesterone receptor-negative tumors.